Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Checkpoint Therapeutics, Inc. CKPT. This Medical - Biomedical and Genetics stock has actually seen estimates rise over the past month for the current fiscal year by about 30%. But that is not yet reflected in its price, as the stock dropped 29.3% over the same time frame.
Checkpoint Therapeutics, Inc. Price and Consensus
Checkpoint Therapeutics, Inc. Price and Consensus | Checkpoint Therapeutics, Inc. Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 16%, which should ultimately translate into price appreciation.
And if this isn’t enough, CKPT currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Checkpoint Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for CKPT and that now might be an interesting buying opportunity.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Checkpoint Therapeutics, Inc. (CKPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
